A team fed aging mice a fatty, sugary diet until their livers went bad, then treated them with two drugs that both aim at the same tiny structure inside cells. Both helped. The interesting part is that they helped in different ways.
The study, published in Physiological Research ↗ by Xiao and colleagues, compared two mitochondria-targeted agents in metabolic dysfunction-associated steatotic liver disease, or MASLD. That is the current name for fatty liver disease driven by metabolic problems rather than alcohol. It is common, it can progress to scarring, cirrhosis, and liver cancer, and it still has almost no approved drug treatment. One reason the liver goes wrong early is that mitochondria, the structures that burn fat and sugar for energy, start to fail. So the researchers went straight at the mitochondria.
The two agents were MitoQ and SS-31. MitoQ is a small antioxidant molecule, a form of the coenzyme Q10 that cells use in energy production, chemically tweaked so it piles up inside mitochondria. It is sold as a supplement, not an approved medicine. SS-31 is the more interesting of the pair. It is a synthetic peptide of just four amino acids, better known now as elamipretide ↗, and it works by clamping onto cardiolipin ↗, a distinctive fat that lines the inner wall of a mitochondrion and holds its folded membranes in shape. Late in 2025 elamipretide became the first mitochondria-targeted drug to win FDA approval, for Barth syndrome, a rare inherited heart and muscle disorder. This liver study asks whether that same repair trick helps a far more common disease.
The setup was deliberately hard. The mice were aged female C57BL/6 mice, 12 to 14 months old, fed a high-fat, high-fructose diet for 16 weeks to bring on MASLD. They were split into four groups: a healthy control diet, untreated MASLD, MASLD plus MitoQ by mouth at 25 milligrams per kilogram a day, and MASLD plus SS-31 by injection at 3 milligrams per kilogram a day. The team then read out a panel of proteins from liver tissue by Western blot, a standard way to gauge how much of a given protein is present, and looked at the tissue itself under the microscope.
Both drugs pushed the failing liver back toward normal, and both raised the proteins that build and maintain mitochondria, including PGC-1 alpha, NRF1, and TFAM, the master regulators of mitochondrial biogenesis. Where they parted ways was the mechanism. MitoQ mostly boosted the cell's antioxidant defenses, raising the protective enzymes SOD2 and Nrf2 and cutting a marker of oxidative damage called 4-HNE. In plain terms, it mopped up the reactive molecules that wear a cell down. SS-31 did less of that and instead did what its cardiolipin grip predicts: it better preserved the physical structure of the mitochondria. One agent defends the chemistry, the other props up the architecture.
From there the two converged. Both quieted the inflammation machinery, lowering NF-kB and the NLRP3 inflammasome, two switches that drive the liver toward scarring. Both improved insulin signaling, raising phosphorylated Akt and the glucose transporter GLUT2, which points to better blood-sugar handling. And under the microscope, both markedly reduced the fat buildup that defines the disease. Two different levers, one shared recovery.
That split is the reason the paper is worth reading, and also the reason to keep expectations low. This is a mouse study, in one sex and one age band, and almost every readout is a protein level or a stained slice rather than a hard functional outcome. The abstract reports directions, not effect sizes, so there is no way to say how large any of the changes were or whether one drug beat the other. The two were not even given the same way, MitoQ by mouth and SS-31 by injection, so a fair head-to-head on potency is not on offer here. And elamipretide's own clinical history is a caution: it has cleared some targeted settings and missed the main goal in larger trials of other mitochondrial diseases. There is no human MASLD data at all.
What the study does is make a specific, testable claim. If mitochondrial failure is an early driver of fatty liver disease, then two drugs that repair mitochondria by different routes should both help, and here they did. On peptidemodel, elamipretide sits as the rare peptide whose target is not a receptor on the cell surface but a lipid deep inside it, the cardiolipin that keeps mitochondrial membranes folded. It has turned up before in an unexpected place, when the same approved peptide slowed radiation-driven aging in lab-grown heart cells ↗. A liver bench study in aged mice is early, but it widens the list of tissues where propping up the cell's power plants looks like it might matter.